This comprehensive study enrolled 163 NSCLC patients presenting AGAs other than the widely studied EGFR, ALK, and ROS1 mutations who received first-line systemic treatments. The cohort was divided into two groups: those treated with a combination of chemotherapy and ICIs (CT + IO), and those who received chemotherapy (CT) alone. Over an extended median follow-up of 32 months, this extensive dataset allowed for a robust comparison of clinical outcomes, shedding light on response rates, progression-free survival (PFS), time to next treatment (TTNT), and overall survival (OS) amongst these patients.

One of the striking features of the study was the molecular diversity of the patient cohort. The distribution included EGFR exon 20 insertion (E20I) mutations in 28.8% of patients, HER2 mutations (mHER2) in 39.9%, RET fusions in 16.6%, and MET exon 14 skipping mutations (METex14) in 14.7%. These genetic alterations, though less frequently targeted by established therapies, represent a growing frontier for personalized treatment efforts in NSCLC. The researchers meticulously documented clinical outcomes for each subset, unearthing distinct patterns of treatment response.

When analyzing the median PFS, patients treated with the CT + IO regimen showed a promising trend compared to those receiving CT alone, with medians of 8.0 months and 6.4 months, respectively. Although the hazard ratio (HR: 0.71) suggested a 29% reduction in the risk of progression or death with the combined therapy, it narrowly missed conventional statistical significance. Despite this, the findings provide a critical foothold for further exploration of chemoimmunotherapy in genetically diverse NSCLC populations.

Delving deeper into the mutation-specific responses within the CT + IO group revealed even more intriguing data. Patients harboring the METex14 mutation exhibited the most favorable outcomes, with a median PFS of 17.1 months, starkly surpassing other genetic cohorts. This subgroup also demonstrated a notably high level of PD-L1 expression, with almost half of the METex14 patients showing PD-L1 tumor proportion scores (TPS) of 50% or higher, potentially explaining their enhanced responsiveness to ICIs. In comparison, patients with EGFR exon 20 insertions and RET fusions exhibited more modest median PFS intervals of 5.0 and 5.8 months, respectively, while HER2-mutated patients had intermediate outcomes.

This stratification is pivotal because PD-L1 expression, a biomarker indicating immune evasion potential by tumors, remains a critical predictor of ICI efficacy. The study’s survival analysis further underscored this relationship: 24-month overall survival rates increased congruently with PD-L1 expression, reaching 81.5% in patients with the highest expression levels (≥ 50% PD-L1 TPS), compared to 45.4% and 56.3% for those with lower levels. These data highlight that PD-L1 status should be integrated into clinical decision-making frameworks when considering immunotherapy, especially in the context of NSCLC with noncanonical AGAs.

Clinicians often face difficult decisions when molecularly targeted therapies are either unavailable or unapproved for rarer genetic alterations in NSCLC. This study offers a valuable contribution in demonstrating that the combination of chemotherapy and ICIs produces clinical benefit comparable to chemotherapy alone, but with certain patient subsets—such as those with METex14 mutations—experiencing significantly enhanced outcomes. These results invite a reassessment of treatment paradigms, especially considering the expanding armamentarium of immunotherapeutic agents.

Moreover, the findings carry implications for the design of future clinical trials, pushing for stratification based on both genetic alteration and PD-L1 expression. They advocate for inclusion criteria that reflect the genetic heterogeneity seen in real-world clinical settings rather than restricting enrollment to predominant mutations like EGFR and ALK fusions. Such an approach could accelerate the development of tailored regimens, improving survival and quality of life for patients with rarer NSCLC subtypes.

Understanding the interplay between immune mechanisms, genetic drivers, and therapeutic responses remains an ongoing scientific quest. This study enriches our appreciation of the variable immune landscape across different AGAs and underscores the importance of precision oncology. From a mechanistic perspective, mutations such as METex14 may influence tumor microenvironment features, rendering tumors more susceptible to immune checkpoint blockade when combined with cytotoxic chemotherapy.

Despite its retrospective design, the study is strengthened by comprehensive molecular profiling and detailed survival analyses, providing a nuanced view of treatment effects in a challenging patient population. However, prospective validation is essential to confirm these findings and optimize integration strategies for chemotherapy and immunotherapy. The potential synergy between DNA damage induced by chemotherapy and immune activation prompted by ICIs deserves further exploration at the molecular and clinical levels.

In the evolving NSCLC treatment landscape, the Samsung Medical Center’s work illuminates a path forward for patients with actionable gene alterations beyond the EGFR, ALK, and ROS1 spectrum. It paves the way for more individualized therapies tailored by genetic and immunologic tumor signatures, expanding therapeutic horizons beyond the conventional. Importantly, it challenges oncologists to consider immune checkpoint inhibitors in combination regimens when targeted options are constrained.

As this study demonstrates, the chemotherapy plus immune checkpoint inhibitor approach does not merely replicate chemotherapy outcomes but may confer distinct benefits in genetically selected subgroups. The pronounced response and prolonged PFS in METex14 patients signals a need for heightened clinical vigilance in recognizing these mutations and tailoring treatment accordingly. Additionally, PD-L1 expression emerges as a critical biomarker that could refine patient selection, maximizing therapeutic efficacy and minimizing unnecessary toxicity.

This research contributes a vital piece to the complex puzzle of NSCLC treatment optimization in the era of personalized medicine. It calls upon the medical and scientific communities to further investigate the nuances of immune response modulation in genetically diverse tumors and to develop innovative clinical strategies that transcend traditional boundaries. This effort holds promise for transforming the prognosis of many NSCLC patients, enabling longer survival and improved quality of life through precision-guided combinatorial approaches.

In conclusion, integrating chemotherapy with immune checkpoint inhibitors in NSCLC patients harboring actionable gene alterations other than EGFR, ALK, and ROS1 mutations offers a viable and potentially superior treatment paradigm, particularly for those with METex14 mutations and elevated PD-L1 expression. This approach exemplifies the power of precision oncology to harness the immune system alongside cytotoxic therapy, illuminating new avenues in the ongoing battle against lung cancer.

Subject of Research: Combination therapy using chemotherapy and immune checkpoint inhibitors in non-small cell lung cancer patients with actionable gene alterations excluding EGFR, ALK, and ROS1 mutations.

Article Title: Combination of chemotherapy and immune checkpoint inhibitors in non-small cell lung cancer with actionable gene alterations other than EGFR, ALK, and ROS1 mutations: a retrospective observational study

Article References: Shin, J.E., Park, S., Jung, H.A. et al. Combination of chemotherapy and immune checkpoint inhibitors in non-small cell lung cancer with actionable gene alterations other than EGFR, ALK, and ROS1 mutations: a retrospective observational study. BMC Cancer 25, 1616 (2025). https://doi.org/10.1186/s12885-025-14834-1

Image Credits: Scienmag.com

DOI: https://doi.org/10.1186/s12885-025-14834-1

Lung adenocarcinoma, a leading cause of cancer-related mortality worldwide, often exhibits a complex tumor immune microenvironment where the interaction between tumor cells and immune cells can dictate disease progression and therapeutic response. The role of TLSs within this microenvironment has garnered significant attention due to their potential in orchestrating local immune responses and improving patient prognosis.

The study, conducted on tissue slides from 120 LUAD patients, employed advanced multiplex immunofluorescence (mIF) techniques to quantify and characterize TLSs and to analyze the immune landscape within tumors and TDLNs. Two distinct staining panels allowed for a comprehensive assessment: the first panel highlighted TLS components such as CD20+ B cells, CD21+ follicular dendritic cells, and CD23+ markers, while the second focused on the broader immune environment, including CD4+ and CD8+ T cells alongside CD20+ B cells.

Remarkably, patients with detectable TLSs exhibited significantly better disease-free survival (DFS) and overall survival (OS) compared to those without TLSs. Median DFS in TLS-positive patients was approximately 71 months, contrasting starkly with 29 months in TLS-negative individuals. Similarly, median OS for TLS-positive groups reached over 77 months, whereas it was not reached for TLS-negative counterparts within the study timeframe, underscoring the prognostic significance of TLS presence.

Delving into the cellular contributors to TLS development, the research identified B cells within both the tumor microenvironment and TDLNs as pivotal players. A higher ratio of tumor-infiltrating B cells to those within TDLNs correlated positively with the abundance of TLSs, suggesting a dynamic migration or expansion mechanism that fosters TLS assembly in tumor tissues.

Beyond mere presence, the functional state of these B cells emerged as crucial. Among the subsets identified, TIM-1-positive B cells in the TDLNs demonstrated a compelling association with impaired TLS maturation. This unique immunosuppressive B cell population seemed to hinder the progression from immature to fully mature TLSs, which are essential for robust anti-tumor immune activity. The inverse correlation between TIM-1+ B cell prevalence and mature TLS percentage highlights a novel immunoregulatory checkpoint that might be exploited therapeutically.

The implications of these findings extend beyond mere biological insight. Targeting TIM-1+ B cells in TDLNs could represent a strategic conduit to enhance TLS maturation, thereby bolstering local anti-tumor immunity and improving clinical outcomes for LUAD patients. This concept aligns with emerging immunotherapeutic paradigms aimed at modulating the tumor immune microenvironment to overcome resistance and enhance efficacy.

Moreover, this research underscores the importance of the lymph node-tumor axis in cancer immunology. While much attention has focused on primary tumors and circulating immune components, the sentinel lymph nodes, particularly those draining the tumor site, appear to function as critical immunological hubs influencing local and systemic responses. Understanding the cellular and molecular crosstalk within these nodes offers new avenues for diagnostic and therapeutic innovations.

The study’s methodological strength lies in its utilization of multiplex immunofluorescence, enabling simultaneous visualization and quantification of multiple immune markers within spatial context. This technique provides a robust platform to dissect complex cellular interactions and heterogeneity that conventional methods might overlook, enriching our understanding of tumor immunobiology.

Clinically, the presence of TLSs detected through non-invasive or minimally invasive biopsy sampling could emerge as a valuable prognostic biomarker, guiding treatment stratification and personalized immunotherapy approaches. Furthermore, monitoring TIM-1+ B cell populations in TDLNs might help predict TLS maturation status and therapeutic responsiveness.

Future research stemming from these findings will likely explore mechanistic pathways by which TIM-1+ B cells suppress TLS maturation, including potential signaling cascades and cellular interactions involved. Additionally, translational studies assessing the efficacy of TIM-1 blockade or depletion strategies in preclinical models could pave the way for novel combinational immunotherapies.

In summary, this pioneering work reveals a sophisticated immunoregulatory network centered on tumor-draining lymph nodes and B cell subsets that govern the formation and maturation of tertiary lymphoid structures in lung adenocarcinoma. By illuminating the dualistic roles of B cells — both supportive in TLS formation and inhibitory via the TIM-1+ subset — the study opens promising therapeutic avenues aimed at harnessing the immune system more effectively against one of the deadliest malignancies.

This paradigm shift promises to refine our approach to lung cancer treatment by targeting not just the tumor but the immune ecosystem integral to cancer progression and control. By enhancing TLS maturity and function, clinicians may soon offer patients improved prognoses and more durable responses to immunotherapy, marking an exciting leap toward precision oncology.

Subject of Research: Lung adenocarcinoma, tertiary lymphoid structures, tumor-draining lymph nodes, B cells, tumor immune microenvironment, immunotherapy

Article Title: Effect of tumor draining lymph nodes in the formation and maturation of tertiary lymphoid structure in patients with lung adenocarcinoma

Article References: Wen, J., Yun, W., Yin, X. et al. Effect of tumor draining lymph nodes in the formation and maturation of tertiary lymphoid structure in patients with lung adenocarcinoma. BMC Cancer 25, 1507 (2025). https://doi.org/10.1186/s12885-025-14913-3

Image Credits: Scienmag.com

DOI: https://doi.org/10.1186/s12885-025-14913-3

The term "doctor shopping" describes the practice of patients visiting multiple physicians or healthcare facilities before receiving definitive treatment. In the context of lung cancer, a diagnosis often triggers urgency and anxiety, prompting patients to seek multiple opinions or treatments in search of the best possible care. However, whether this behavior confers a survival advantage or poses risks had remained largely unquantified until now. Leveraging Korea’s National Health Insurance Service database, which compiles exhaustive claims data nationwide, the team led by Hong et al. undertook a rigorous examination of this behavior over a decade-plus timespan.

Using a well-curated cancer cohort that excluded patients based on specific criteria to ensure data robustness, the researchers identified 280,030 newly diagnosed lung cancer patients from 2009 to 2021. They meticulously tracked the number of doctor visits each patient undertook between the time of initial diagnosis and the commencement of treatment. This parameter, dubbed doctor-shopping behavior (DSB), was thoughtfully divided into four groups based on quartiles: minimal visits (Q1), moderate visits (Q2 and Q3), and excessive visits (Q4), allowing for nuanced analysis of its effects on mortality and survival.

Death rates were scrutinized at multiple time points: within 30 days, 90 days, and one year post-diagnosis, as well as overall survival beyond five years. Employing advanced multiple logistic regression models, the team adjusted for confounding variables to isolate the influence of doctor-shopping behaviors on patient outcomes. This methodological rigor ensured that the observed associations were not mere artifacts but reflected genuine trends with clinical significance.

Intriguingly, the findings revealed a protective effect associated with moderate doctor shopping. Patients who engaged in two to nine visits before treatment initiation exhibited a lower probability of dying within the initial critical periods after diagnosis — 30 days, 90 days, and one year — compared to those who had minimal or no doctor visits. Furthermore, these moderately engaged patients demonstrated a significantly increased likelihood of surviving beyond five years, a remarkable insight considering lung cancer’s generally poor prognosis.

In stark contrast, the cohort with excessive doctor shopping, defined as more than ten visits prior to treatment onset, experienced markedly worse outcomes. The odds of mortality were significantly heightened across all measured time intervals for this group. Notably, their probability of surviving past five years decreased by approximately 12% compared to minimal visitors, indicating that excessive medical wandering might delay timely treatment or provoke fragmented care that harms survival.

The study’s stratified analysis further revealed socioeconomic and geographical disparities accentuating the risks of doctor shopping. Middle-class or wealthier individuals residing in metropolitan areas who exhibited excessive doctor-shopping patterns showed a 14–18% increase in mortality within the first year of diagnosis and a 12–18% reduction in five-year survival rates compared to their counterparts with limited doctor visits. Such patterns could reflect greater access to numerous specialists, potentially leading to treatment delays or inconsistent care pathways.

These insights carry profound implications for healthcare policy and clinical practice. Lung cancer, a leading cause of cancer mortality worldwide, demands streamlined, high-quality care pathways to optimize outcomes. While seeking additional medical opinions can empower patients, excessive switching between providers without coordinated care may undermine treatment efficacy. Accordingly, the authors advocate for policies that regulate doctor-shopping tendencies, especially among patient groups with substantial healthcare access, to promote judicious use of medical resources and enhance survival outcomes.

Beyond survival statistics, this study underscores the importance of patient guidance and system-level interventions in oncology care. Educating patients about the risks and benefits of consulting multiple providers, coupled with improving referral systems and care continuity, could alleviate deleterious doctor-shopping behaviors. Meanwhile, healthcare providers should be attuned to patterns indicative of excessive doctor-shopping to address underlying concerns proactively.

This research also capitalizes on the power of claims data analytics, demonstrating how large-scale administrative datasets can inform epidemiological insights and health services research. The Korean National Health Insurance Service database’s comprehensiveness allowed for granular investigation across a national population, overcoming typical limitations of small sample sizes or single institution studies that often restrict generalizability.

Importantly, this study’s temporal breadth, covering over a decade, enabled the observation of long-term outcomes and trends that shorter studies cannot capture. The stability of the associations between DSB and survival over such an extended period strengthens confidence in the findings and highlights persistent patterns relevant for policymaking over time.

The revelation that moderate doctor shopping confers a survival benefit invites further research into the mechanisms involved. It is plausible that consulting multiple physicians facilitates second opinions, earlier detection of complications, or selection of optimal treatments. Conversely, analysis of the biological or psychological factors linked with excessive doctor shopping could reveal patient anxieties, systemic barriers, or healthcare inefficiencies underpinning poorer outcomes.

Moreover, the study sheds light on disparities in access and utilization of healthcare services in metropolitan versus rural settings, underscoring broader public health challenges. Strategies tailored to urban environments, where the temptation or opportunity for excessive doctor shopping is higher, may require nuanced intervention approaches distinct from rural areas.

The authors conclude by emphasizing the delicate balance between empowering patient autonomy and safeguarding clinical effectiveness. Optimizing lung cancer survival hinges not only on advanced therapies but also on effective healthcare navigation. Their findings challenge us to rethink how patients engage with medical systems and prompt the integration of behavioral insights into cancer care models.

This study represents a compelling advancement in understanding how patients’ behavior before treatment initiation directly impacts survival outcomes in lung cancer. As healthcare systems worldwide grapple with optimizing resource allocation, these findings provide evidence that could shape future clinical guidelines and health policy reforms, ensuring more efficient and equitable cancer care delivery.

Hong, M., Yun, I., and Moon, J.Y.’s landmark study offers a vital roadmap for researchers, clinicians, and policymakers aiming to reconcile patient behaviors with outcome improvements in oncology. In an era where lung cancer therapies are rapidly evolving, such epidemiological analyses remain critical in informing holistic patient management strategies that go beyond the molecular and clinical to include behavioral dimensions.

Subject of Research: Impact of doctor-shopping behavior on survival outcomes in lung cancer patients in Korea.

Article Title: Impact of doctor-shopping behavior on patient survival in lung cancer: findings from a 11-year cohort study using Korean claims data.

Article References:
Hong, M., Yun, I. & Moon, J.Y. Impact of doctor-shopping behavior on patient survival in lung cancer: findings from a 11-year cohort study using Korean claims data. BMC Cancer 25, 914 (2025). https://doi.org/10.1186/s12885-024-13416-x

Image Credits: Scienmag.com

DOI: https://doi.org/10.1186/s12885-024-13416-x